Japanese firm establishes Singapore subsidiary

Sunovion Pharmaceuticals Asia Pacific will be the base for its operations in Southeast Asia

Singapore operations will be key to DSP in expanding its product line-ups in Southeast Asia

Singapore: Dainippon Sumitomo Pharma (DSP), a pharmaceutical company headquartered in Osaka, Japan, has established a wholly owned subsidiary in Singapore as a base of operations in Southeast Asia. The subsidiary is called Sunovion Pharmaceuticals Asia Pacific.

DSP is expanding globally with its global strategic product, antipsychotic lurasidone hydrochloride (generic name) at the core. As a part of this effort, DSP has considered extending commercial operations for lurasidone hydrochloride to countries in Southeast Asia where growth is expected in the mid-to long term.

DSP will first promote business operations such as obtaining approval for and marketing lurasidone hydrochloride in Southeast Asia through partnerships with local companies. In future, using Singapore as a base of operations, DSP will consider successive expansion of its product line-ups in Southeast Asia and additionally business expansion into neighboring countries such as Australia.